Quantum Biopharma (QNTM) EBITDA (2019 - 2026)

Quantum Biopharma (QNTM) has 8 years of EBITDA data on file, last reported at -$3.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 12.69% year-over-year to -$3.0 million; the trailing twelve-month figure through Mar 2026 stood at -$14.9 million (down 13.29% YoY), and the FY2025 full-year result was -$15.3 million, up 5.17% from the prior year.
• EBITDA fell to -$3.0 million in Q1 2026, from -$2.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $5.6 million in Q1 2022 to a low of -$9.8 million in Q1 2023.
• A 5-year average of -$3.1 million and a median of -$3.4 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 274.26% in 2023 and soared 77.07% in 2024, its largest moves.
• Tracing QNTM's EBITDA over 5 years: stood at $5.6 million in 2022, then tumbled by 158.62% to -$3.3 million in 2023, then soared by 36.85% to -$2.1 million in 2024, then dropped by 13.48% to -$2.4 million in 2025, then declined by 24.98% to -$3.0 million in 2026.
• Business Quant data shows QNTM's EBITDA at -$3.0 million in Q1 2026, -$2.4 million in Q4 2025, and -$4.7 million in Q3 2025.